Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: A. Menarini Pharmaceuticals Ireland Ltd, Castlecourt, Monkstown Farm, Monkstown, Glenageary, Co Dublin, Ireland
Siofor SR 500 mg prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. White to off-white, capsule shaped tablet, debossed on one side with ‘SR 500’ and plain on the other side. Tablet dimensions: length 16.50 mm, breadth 8.20 mm, thickness 6.10 mm. |
Each prolonged-release tablet contains 500 mg metformin hydrochloride corresponding to 390 mg metformin base.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Metformin |
Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. |
| List of Excipients |
|---|
|
Magnesium stearate |
15, 30, 60, 90 or 120 prolonged-release tablets in blister strips composed of aluminium foil and PVC.
Not all pack sizes may be marketed.
A. Menarini Pharmaceuticals Ireland Ltd, Castlecourt, Monkstown Farm, Monkstown, Glenageary, Co Dublin, Ireland
PA1833/002/001
Date of first authorisation: 3rd May 2019
| Drug | Countries | |
|---|---|---|
| SIOFOR | Albania, Germany, Croatia, Ireland, Poland, Romania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
